

## ICMJE DISCLOSURE FORM

**Date:** 10/11/2023

**Your Name:** Hiroko H Dodge

**Manuscript Title:** One step forward to personalized medicine?

**Manuscript Number (if known):** [Click or tap here to enter text.](#)

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
<b>Time frame: Since the initial planning of the work</b>									
<b>1</b>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input type="checkbox"/> <b>None</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; padding: 2px;">NIA R01AG056712</td> <td style="width: 30%;"></td> </tr> <tr> <td style="padding: 2px;">NIA P30AG066518</td> <td></td> </tr> <tr> <td colspan="2" style="text-align: right; padding: 2px;"><small>Click the tab key to add additional rows.</small></td> </tr> </table>	NIA R01AG056712		NIA P30AG066518		<small>Click the tab key to add additional rows.</small>	
NIA R01AG056712									
NIA P30AG066518									
<small>Click the tab key to add additional rows.</small>									
<b>Time frame: past 36 months</b>									
<b>2</b>	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> <b>None</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; padding: 2px;">FROM NIH:</td> <td></td> </tr> <tr> <td style="padding: 2px;">R01AG051628, R01AG056102, U2CAG054397, P30AG053760, R01AG042191, P01AG043362, R01AG043398, U01NS100611, U2CAG057441, U01NS106670, R01AG054484, R01AG058687, P30 AG024978, R01AG042191, R01AG038651</td> <td></td> </tr> </table>	FROM NIH:		R01AG051628, R01AG056102, U2CAG054397, P30AG053760, R01AG042191, P01AG043362, R01AG043398, U01NS100611, U2CAG057441, U01NS106670, R01AG054484, R01AG058687, P30 AG024978, R01AG042191, R01AG038651			
FROM NIH:									
R01AG051628, R01AG056102, U2CAG054397, P30AG053760, R01AG042191, P01AG043362, R01AG043398, U01NS100611, U2CAG057441, U01NS106670, R01AG054484, R01AG058687, P30 AG024978, R01AG042191, R01AG038651									
<b>3</b>	Royalties or licenses	<input checked="" type="checkbox"/> <b>None</b>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 70%; height: 20px;"></td> <td></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	<input checked="" type="checkbox"/> <b>None</b>	
		Northwestern ADC	
		Florida1 ADC	
		Centers of Biomedical Research Excellence (COBRE) at U of Hawaii	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> <b>None</b>	
		IMPACT-AD workshop supported by ACTC	
6	Payment for expert testimony	<input checked="" type="checkbox"/> <b>None</b>	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> <b>None</b>	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> <b>None</b>	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> <b>None</b>	
		Data Safety Monitoring Board member for the following trials: US POINTER (Protect Brain Health Through Lifestyle Intervention to Reduce Risk, PI: Laura Barker), RAATE (Reducing African Americans' Alzheimer's Disease Risk Through Exercise, PI: Robert Newton), BEST-AD (the Brain Energy for Amyloid Transformation in AD, PI: Suzanne Craft) and Stomp-AD (Senolytic Therapy to Modulate the Progression of Alzheimer's Disease, PI: Miranda Orr).	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
		ISTAART Advisory Committee member (2018-2021)	
		ISTAART Clinical Trials Method PIA founding chair (2017-2020)	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

**Date:** 10/10/2023

**Your Name:** Steven E. Arnold

**Manuscript Title:** One Step Forward to Personalized Medicine?

**Manuscript Number (if known):** Click or tap here to enter text.

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																				
Time frame: Since the initial planning of the work																						
<b>1</b>	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	<input type="checkbox"/> None <b>Commercial Entity Sponsored Grant Support. - ALL to Institution</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td>Abbvie, Inc.</td><td>2019, 2020, 2021, 2023</td></tr> <tr><td>Amylyx Inc.</td><td>2019, 2020, 2021, 2022, 2023</td></tr> <tr><td>Athira Pharma Inc.</td><td>2021, 2022, 2023</td></tr> <tr><td>Chromadex, Inc.</td><td>2020, 2021, 2022</td></tr> <tr><td>EIP Pharama, Inc.</td><td>2020, 2021</td></tr> <tr><td>Janssen Pharmaceuticals, Inc.</td><td>2021, 2022, 2023</td></tr> <tr><td>Novartis aG</td><td>2021, 2022, 2023</td></tr> <tr><td>Seer Biosciences, Inc.</td><td>2021, 2022, 2023</td></tr> <tr><td>vTv Therapeutics, Inc.</td><td>2020</td></tr> <tr><td>AC Immune SA.</td><td>2021, 2022</td></tr> </table>	Abbvie, Inc.	2019, 2020, 2021, 2023	Amylyx Inc.	2019, 2020, 2021, 2022, 2023	Athira Pharma Inc.	2021, 2022, 2023	Chromadex, Inc.	2020, 2021, 2022	EIP Pharama, Inc.	2020, 2021	Janssen Pharmaceuticals, Inc.	2021, 2022, 2023	Novartis aG	2021, 2022, 2023	Seer Biosciences, Inc.	2021, 2022, 2023	vTv Therapeutics, Inc.	2020	AC Immune SA.	2021, 2022
Abbvie, Inc.	2019, 2020, 2021, 2023																					
Amylyx Inc.	2019, 2020, 2021, 2022, 2023																					
Athira Pharma Inc.	2021, 2022, 2023																					
Chromadex, Inc.	2020, 2021, 2022																					
EIP Pharama, Inc.	2020, 2021																					
Janssen Pharmaceuticals, Inc.	2021, 2022, 2023																					
Novartis aG	2021, 2022, 2023																					
Seer Biosciences, Inc.	2021, 2022, 2023																					
vTv Therapeutics, Inc.	2020																					
AC Immune SA.	2021, 2022																					
Time frame: past 36 months																						
<b>2</b>	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <b>Non Profit Entity Sponsored Grant Support. - ALL to Institution</b> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td>Alzheimer's Association</td><td>2020, 2021, 2022, 2023</td></tr> <tr><td>Alzheimer's Drug Discovery Foundation</td><td>2019, 2020, 2021, 2022</td></tr> <tr><td>Challenger Foundation</td><td>2019, 2020, 2021, 2022, 2023</td></tr> <tr><td>John Sperling Foundation</td><td>2021, 2022</td></tr> <tr><td>National Institutes of Health</td><td>2019, 2020, 2021, 2022, 2023</td></tr> </table>	Alzheimer's Association	2020, 2021, 2022, 2023	Alzheimer's Drug Discovery Foundation	2019, 2020, 2021, 2022	Challenger Foundation	2019, 2020, 2021, 2022, 2023	John Sperling Foundation	2021, 2022	National Institutes of Health	2019, 2020, 2021, 2022, 2023										
Alzheimer's Association	2020, 2021, 2022, 2023																					
Alzheimer's Drug Discovery Foundation	2019, 2020, 2021, 2022																					
Challenger Foundation	2019, 2020, 2021, 2022, 2023																					
John Sperling Foundation	2021, 2022																					
National Institutes of Health	2019, 2020, 2021, 2022, 2023																					

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	<input checked="" type="checkbox"/> None	
4	Consulting fees	<input type="checkbox"/> None	
		Daewoong Pharmaceutical Co.	2022
		EIP Pharma Inc.	2019, 2020
		Risen Pharmaceutical Technology Co, LTD.	2021
		NeuroSense Therapeutics	2023
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	
		Eisai	2021
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
		Boyle Shaughnessy Law	2021
7	Support for attending meetings and/or travel	<input type="checkbox"/> None	
8	Patents planned, issued or pending	<input type="checkbox"/> None	
		Meso Scale Discovery, LLC.	Co-inventor on a patent application relating to assays for neurological biomarkers, pending
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	
		Allyx Therapeutics, Ins. (SAB)	2022, 2023
		Bob's Last Marathon (SAB)	2020, 2021, 2022, 2023
		BioVie	2023

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Cortexyme, Inc. /Quince Therapeutics(DSMB)	2020, 2021, 2022
		Sage Therapeutics, (SAB)	2020, 2021, 2022
		Jocasta Neuroscience; Vandria SA	2023; 2023
<b>10</b>	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> <b>None</b>	
<b>11</b>	Stock or stock options	<input checked="" type="checkbox"/> <b>None</b>	
<b>12</b>	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> <b>None</b>	
<b>13</b>	Other financial or non-financial interests	<input checked="" type="checkbox"/> <b>None</b>	

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.